BioNTech and Bristol Myers Squibb reported promising Phase 2 results for pumitamig combined with docetaxel in advanced non-small cell lung cancer (NSCLC) patients who progressed after immunotherapy plus chemotherapy. The treatment showed a confirmed objective response rate of 36.7% and median progression-free survival of 6.9 months, outperforming the standard docetaxel care with PFS below 4 months. Responses were seen across different NSCLC subtypes and PD-L1 expression levels, with manageable safety. These findings support further development of pumitamig as a new option for patients with limited treatments after immunotherapy failure.
Following the promising Phase 2 data for pumitamig in advanced NSCLC reported by BioNTech and Bristol Myers Squibb, both stocks are experiencing declines on Pluang as of Oct 25, 2026, 14:41 WIB. BioNTech (BNTX) trades at USD 88.11, down 1.73% for the day, while Bristol-Myers Squibb (BMY) is priced at USD 61.48, down 2.41%. Notably, Bristol-Myers Squibb shows strong sell activity at 100% on Pluang, reflecting cautious investor sentiment despite the encouraging clinical results.
Moderna's stock dropped 25% after a late-stage melanoma vaccine report was briefly posted online and then removed. The vaccine, developed with Merck, showed favorable results in reducing melanoma recurrence or death when combined with Keytruda, but t...
BioNTech announced a collaboration with Gilead Sciences to test pumitamig combined with sacituzumab govitecan in a Phase 3 trial for PD-L1 low or negative triple-negative breast cancer (TNBC). This trial, ROSETTA Breast-01, will replace chemotherapy ...
BioNTech SE will announce its financial results for the third quarter of 2026 on November 3, 2026, followed by a conference call and webcast for investors and the public. The company, known for its innovative cancer therapies and mRNA technology, wil...
